Chris Waskewich

Statistics

Publications

Citations

254

H-Index

Active since

2001

Affiliations

Center for Molecular Medicine and Immunology(Current)

Chris Waskewich is an author at Center for Molecular Medicine and Immunology specializing in cyclooxygenase inhibitors, oncology pharmacotherapy, and pharmacology.

Publications per year

2001–2002

Publications

Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines.

Chris Waskewich, Rosalyn D. Blumenthal, Honglan Li et al. · PubMed · 2002 · 203 citations

Medicine, Oncology, Pharmacology +13

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

Rosalyn D. Blumenthal, Chris Waskewich, David M. Goldenberg et al. · PubMed · 2001 · 51 citations

Medicine, Oncology, Pharmacology +16

1–2 of 2